Hemoglobinopathy

Summary

Hemoglobinopathy (MONDO:0044348) is a disease with 2 cohort genes and 66 clinical trials. Top therapeutic interventions include exagamglogene autotemcel, hydroxyurea, and penicillin g.

At a glance

• Cohort genes: 2
• ClinVar variants: 56
• Clinical trials: 66

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemoglobinopathy
Mondo ID	MONDO:0044348
SNOMED CT	80141007
UMLS	C0019045
MedGen	42400
Is cancer (heuristic)	no

Also known as: haemoglobin disease · haemoglobin disorder · hemoglobinopathy

Data availability: 56 ClinVar variants.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › erythrocyte disorder › hemoglobinopathy

Related subtypes (1): malaria

Subtypes (4): methemoglobinemia, sulfhemoglobinemia, inherited hemoglobinopathy, acquired hemoglobinopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

56 retrieved; paginated sample, class counts are floors:

33 pathogenic, 8 pathogenic/likely pathogenic, 7 likely pathogenic, 6 conflicting classifications of pathogenicity, 2 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
15166	NM_000518.5(HBB):c.71_73del (p.Val24del)	HBB	Pathogenic	no assertion criteria provided
15183	NM_000518.4(HBB):c.86T>C (p.Leu29Pro)	HBB	Pathogenic	criteria provided, single submitter
15239	NM_000518.5(HBB):c.82G>T (p.Ala28Ser)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15241	NM_000518.5(HBB):c.295G>A (p.Val99Met)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15290	NM_000518.5(HBB):c.404T>A (p.Val135Glu)	HBB	Pathogenic	no assertion criteria provided
15300	NM_000518.5(HBB):c.61G>A (p.Val21Met)	HBB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
15311	NM_000518.5(HBB):c.273G>C (p.Glu91Asp)	HBB	Pathogenic	criteria provided, single submitter
15342	NM_000518.5(HBB):c.328G>A (p.Val110Met)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15405	NM_000518.5(HBB):c.114G>A (p.Trp38Ter)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15414	NM_000518.5(HBB):c.51del (p.Lys18fs)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15423	NM_000518.5(HBB):c.36del (p.Thr13fs)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15426	NM_000518.5(HBB):c.45dup (p.Trp16fs)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15431	NM_000518.5(HBB):c.112del (p.Trp38fs)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15432	NM_000518.5(HBB):c.85dup (p.Leu29fs)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15483	NM_000518.5(HBB):c.380T>G (p.Val127Gly)	HBB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
15488	NM_000518.5(HBB):c.*111A>G	HBB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
15494	NM_000518.4(HBB):c.277C>A (p.His93Asn)	HBB	Pathogenic	no assertion criteria provided
15526	NM_000518.5(HBB):c.347C>A (p.Ala116Asp)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15536	NM_000518.4(HBB):c.202G>A (p.Val68Met)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
15545	NM_000518.4(HBB):c.422C>T (p.Ala141Val)	HBB	Pathogenic	criteria provided, single submitter
2573434	NM_000518.5(HBB):c.15_19delinsATCTT (p.Pro6_Glu7delinsSerTer)	HBB	Pathogenic	criteria provided, single submitter
2577315	NM_000518.5(HBB):c.118_121dup (p.Arg41fs)	HBB	Pathogenic	criteria provided, single submitter
2691364	NM_000518.5(HBB):c.345_348dup (p.His117fs)	HBB	Pathogenic	criteria provided, single submitter
38650	NM_000518.5(HBB):c.79G>T (p.Glu27Ter)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
38659	NM_000518.5(HBB):c.155del (p.Pro52fs)	HBB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
393701	NM_000518.5(HBB):c.-138C>A	HBB	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
393702	NM_000518.5(HBB):c.-29G>A	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
439140	NM_000518.5(HBB):c.1A>G (p.Met1Val)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
439167	NM_000518.5(HBB):c.93-2A>C	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts
439782	NM_000518.5(HBB):c.113G>A (p.Trp38Ter)	HBB	Pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 32 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
HBB	Orphanet:2132	Hemoglobin C disease
HBB	Orphanet:2133	Hemoglobin E disease
HBB	Orphanet:231214	Beta-thalassemia major
HBB	Orphanet:231222	Beta-thalassemia intermedia
HBB	Orphanet:231226	Unstable beta globin chain variant disease
HBB	Orphanet:231237	Delta-beta-thalassemia
HBB	Orphanet:231242	Hemoglobin C-beta-thalassemia syndrome
HBB	Orphanet:231249	Hemoglobin E-beta-thalassemia syndrome
HBB	Orphanet:232	Sickle cell anemia
HBB	Orphanet:247511	Autosomal dominant secondary polycythemia
HBB	Orphanet:251365	Sickle cell S-C disease
HBB	Orphanet:251370	Sickle cell S-D Punjab disease
HBB	Orphanet:251375	Sickle cell S-E disease
HBB	Orphanet:251380	Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome
HBB	Orphanet:330041	Hemoglobin M disease
HBB	Orphanet:46532	Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome
HBB	Orphanet:695140	Sickle cell-beta zero-thalassemia
HBB	Orphanet:695147	Sickle cell-beta plus-thalassemia
HBB	Orphanet:699822	Sickle cell S-Lepore disease
HBB	Orphanet:700090	Sickle cell S-O Arab disease
HBB	Orphanet:700107	Sickle cell S-other specified hemoglobin variant
HBB	Orphanet:700111	Homozygous hemoglobin O Arab disease
HBB	Orphanet:715125	Hemoglobin E-beta-thalassemia intermedia
HBB	Orphanet:715128	Hemoglobin E-beta-thalassemia major
HBB	Orphanet:715135	Hemoglobin Lepore-beta-thalassemia intermedia
HBB	Orphanet:715140	Hemoglobin Lepore-beta-thalassemia major
HBB	Orphanet:715143	Heterozygous beta-thalassemia intermedia with supernumerary alpha-globin gene
HBB	Orphanet:715157	Low oxygen affinity beta chain hemoglobin disease
HBB	Orphanet:90039	Hemoglobin D disease
HBD	Orphanet:231237	Delta-beta-thalassemia
HBD	Orphanet:330032	Hemoglobin Lepore-beta-thalassemia syndrome
HBD	Orphanet:699822	Sickle cell S-Lepore disease

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
HBB	HGNC:4827	ENSG00000244734	P68871	Hemoglobin subunit beta	clinvar
HBD	HGNC:4829	ENSG00000223609	P02042	Hemoglobin subunit delta	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
HBB	Hemoglobin subunit beta	Involved in oxygen transport from the lung to the various peripheral tissues.
HBD	Hemoglobin subunit delta	Involved in oxygen transport from the lung to the various peripheral tissues.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	2	1.8×	0.312

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
HBB	Other/Unknown	no		Globin, Hemoglobin_b, Globin-like_sf
HBD	Other/Unknown	no		Globin, Hemoglobin_b, Globin-like_sf

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
trabecular bone tissue	2
monocyte	1
vena cava	1
bone marrow	1
bone marrow cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
HBB	284	broad	marker	monocyte, trabecular bone tissue, vena cava
HBD	170	tissue_specific	marker	trabecular bone tissue, bone marrow, bone marrow cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HBD	1,206
HBB	454

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HBB	P68871	350
HBD	P02042	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Factors involved in megakaryocyte development and platelet production	2	66.4×	0.002	HBB, HBD
Heme assimilation	1	1903.3×	0.003	HBB
Erythrocytes take up oxygen and release carbon dioxide	1	634.4×	0.005	HBB
Erythrocytes take up carbon dioxide and release oxygen	1	439.2×	0.005	HBB
Scavenging of heme from plasma	1	439.2×	0.005	HBB
Chaperone Mediated Autophagy	1	248.3×	0.007	HBB
Late endosomal microautophagy	1	163.1×	0.009	HBB
Heme signaling	1	107.7×	0.012	HBB
Cytoprotection by HMOX1	1	92.1×	0.012	HBB
Neutrophil degranulation	1	11.5×	0.085	HBB

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
carbon dioxide transport	2	1296.3×	5e-06	HBB, HBD
oxygen transport	2	1053.2×	5e-06	HBB, HBD
erythrocyte development	2	526.6×	2e-05	HBB, HBD
nitric oxide transport	1	1685.2×	0.002	HBB
cellular oxidant detoxification	1	936.2×	0.003	HBB
renal absorption	1	842.6×	0.003	HBB
hydrogen peroxide catabolic process	1	337.0×	0.005	HBB
blood vessel diameter maintenance	1	312.1×	0.005	HBB
response to hydrogen peroxide	1	234.1×	0.006	HBB
positive regulation of nitric oxide biosynthetic process	1	227.7×	0.006	HBB
platelet aggregation	1	168.5×	0.007	HBB
regulation of blood pressure	1	110.9×	0.010	HBB
inflammatory response	1	18.9×	0.052	HBB

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
HBB	CANDESARTAN CILEXETIL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
HBB	23	4
HBD	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CANDESARTAN CILEXETIL	4	HBB
MECHLORETHAMINE HYDROCHLORIDE	4	HBB
PHENAZOPYRIDINE HYDROCHLORIDE	4	HBB
MERCAPTOPURINE ANHYDROUS	4	HBB
AZACITIDINE	4	HBB
AZATHIOPRINE	4	HBB
TOPOTECAN HYDROCHLORIDE	4	HBB
ACYCLOVIR	4	HBB
FLUOROURACIL	4	HBB
RAUWOLFIA SERPENTINA	4	HBB
HYDROQUINONE	4	HBB
MENADIONE	4	HBB
THIOTEPA	4	HBB
THIOGUANINE	4	HBB
RESERPINE	4	HBB
CURCUMIN	3	HBB
HYDROXYCAMPTOTHECIN	3	HBB
MOLIBRESIB	2	HBB
FISETIN	2	HBB
TEROXIRONE	2	HBB
5-FLUOROURIDINE	2	HBB
ELLAGIC ACID	2	HBB
BAICALEIN	2	HBB

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
HBB	68	Binding:50, Functional:18

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

23 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
CANDESARTAN CILEXETIL	4	HBB
MECHLORETHAMINE HYDROCHLORIDE	4	HBB
PHENAZOPYRIDINE HYDROCHLORIDE	4	HBB
MERCAPTOPURINE ANHYDROUS	4	HBB
AZACITIDINE	4	HBB
AZATHIOPRINE	4	HBB
TOPOTECAN HYDROCHLORIDE	4	HBB
ACYCLOVIR	4	HBB
FLUOROURACIL	4	HBB
RAUWOLFIA SERPENTINA	4	HBB
HYDROQUINONE	4	HBB
MENADIONE	4	HBB
THIOTEPA	4	HBB
THIOGUANINE	4	HBB
RESERPINE	4	HBB
CURCUMIN	3	HBB
HYDROXYCAMPTOTHECIN	3	HBB
MOLIBRESIB	2	HBB
FISETIN	2	HBB
TEROXIRONE	2	HBB
5-FLUOROURIDINE	2	HBB
ELLAGIC ACID	2	HBB
BAICALEIN	2	HBB

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	HBB
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	HBD

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
HBD	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 66.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	26
PHASE2	14
PHASE1/PHASE2	8
PHASE3	7
PHASE1	5
PHASE4	2
PHASE2/PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00673608	PHASE4	COMPLETED	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
NCT00887081	PHASE4	UNKNOWN	Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
NCT04208529	PHASE3	ENROLLING_BY_INVITATION	A Long-term Follow-up Study in Participants Who Received CTX001
NCT05329649	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05356195	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05477563	PHASE3	RECRUITING	Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT00000585	PHASE3	COMPLETED	Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
NCT00000586	PHASE3	COMPLETED	Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
NCT00000592	PHASE3	COMPLETED	Stroke Prevention in Sickle Cell Anemia (STOP 1)
NCT03655678	PHASE2/PHASE3	COMPLETED	A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
NCT03745287	PHASE2/PHASE3	COMPLETED	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
NCT00920972	PHASE1/PHASE2	RECRUITING	Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT01050855	PHASE2	ACTIVE_NOT_RECRUITING	Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
NCT01966367	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
NCT03128996	PHASE1/PHASE2	RECRUITING	Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
NCT04356469	PHASE2	RECRUITING	TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
NCT04644016	PHASE2	RECRUITING	Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
NCT04853576	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
NCT05444894	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
NCT06490601	PHASE2	ACTIVE_NOT_RECRUITING	Long Term Beta Thalassemia Treatment: Findings From The Extension Period
NCT06839456	PHASE1/PHASE2	RECRUITING	Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06872333	PHASE2	RECRUITING	Allo HSCT for High Risk Hemoglobinopathies
NCT00000588	PHASE2	COMPLETED	Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
NCT00000595	PHASE2	COMPLETED	Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000602	PHASE2	COMPLETED	Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
NCT00001958	PHASE2	COMPLETED	Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia)
NCT00034528	PHASE2	TERMINATED	Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
NCT00040417	PHASE2	TERMINATED	Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
NCT00040469	PHASE2	TERMINATED	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT00153985	PHASE2	COMPLETED	Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
NCT00968864	PHASE2	TERMINATED	T-cell Depleted Alternative Donor Transplantation
NCT02065869	PHASE1/PHASE2	TERMINATED	Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
NCT03733249	PHASE1/PHASE2	TERMINATED	Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
NCT03249831	PHASE1	ACTIVE_NOT_RECRUITING	A Blood Stem Cell Transplant for Sickle Cell Disease
NCT07087262	PHASE1	RECRUITING	A Phase I Study of SNH-119014 in Healthy Volunteers
NCT00744692	PHASE1	COMPLETED	Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
NCT02231710	PHASE1	TERMINATED	Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
NCT02986698	PHASE1	TERMINATED	In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
NCT06107400	EARLY_PHASE1	RECRUITING	Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
NCT06313398	EARLY_PHASE1	RECRUITING	Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EXAGAMGLOGENE AUTOTEMCEL	4	6
HYDROXYUREA	4	3
PENICILLIN G	4	3
PHENYTOIN	4	2
ALEMTUZUMAB	4	1
DEFERASIROX	4	1
DEFEROXAMINE	4	1
PENTOSTATIN	4	1
RIBAVIRIN	4	1
RIMIDUCID	2	3
RENIZGAMGLOGENE AUTOGEDTEMCEL	2	2
RIVOGENLECLEUCEL	2	2
CHEMBL4635234	0	1